Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Research & Development (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Research & Development for 15 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 167.22% year-over-year to $3.5 million, compared with a TTM value of $7.8 million through Sep 2025, up 41.21%, and an annual FY2024 reading of $5.3 million, up 32.57% over the prior year.
  • Research & Development was $3.5 million for Q3 2025 at BioRestorative Therapies, up from $2.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.5 million in Q3 2025 and bottomed at $160898.0 in Q2 2021.
  • Average Research & Development over 5 years is $1.1 million, with a median of $902891.0 recorded in 2023.
  • The sharpest move saw Research & Development surged 568.26% in 2022, then plummeted 49.47% in 2024.
  • Year by year, Research & Development stood at $165496.0 in 2021, then skyrocketed by 307.03% to $673621.0 in 2022, then rose by 1.04% to $680631.0 in 2023, then tumbled by 49.47% to $343915.0 in 2024, then skyrocketed by 925.64% to $3.5 million in 2025.
  • Business Quant data shows Research & Development for BRTX at $3.5 million in Q3 2025, $2.2 million in Q2 2025, and $1.7 million in Q1 2025.